Next Article in Journal
New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases
Next Article in Special Issue
TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities
Previous Article in Journal
Influence of Iron on Bone Homeostasis
Previous Article in Special Issue
Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging
Review

Aptamer-iRNAs as Therapeutics for Cancer Treatment

1
Molecular Therapy Program, Aptamer Core, Center for the Applied Medical Research (CIMA), University of Navarra (UNAV), 31008 Pamplona, Spain
2
Navarre Health Research Institute (IdiSNA), 31008 Pamplona, Spain
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2018, 11(4), 108; https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040108
Received: 28 August 2018 / Revised: 4 October 2018 / Accepted: 10 October 2018 / Published: 18 October 2018
(This article belongs to the Special Issue Aptamer-Based Diagnostics and Therapeutics)
Aptamers are single-stranded oligonucleotides (ssDNA or ssRNA) that bind and recognize their targets with high affinity and specificity due to their complex tertiary structure. Aptamers are selected by a method called SELEX (Systematic Evolution of Ligands by EXponential enrichment). This method has allowed the selection of aptamers to different types of molecules. Since then, many aptamers have been described for the potential treatment of several diseases including cancer. It has been described over the last few years that aptamers represent a very useful tool as therapeutics, especially for cancer therapy. Aptamers, thanks to their intrinsic oligonucleotide nature, present inherent advantages over other molecules, such as cell-based products. Owing to their higher tissue penetrability, safer profile, and targeting capacity, aptamers are likely to become a novel platform for the delivery of many different types of therapeutic cargos. Here we focus the review on interfering RNAs (iRNAs) as aptamer-based targeting delivered agents. We have gathered the most reliable information on aptamers as targeting and carrier agents for the specific delivery of siRNAs, shRNA, microRNAs, and antisense oligonucleotides (ASOs) published in the last few years in the context of cancer therapy. View Full-Text
Keywords: aptamer; cancer; iRNA; siRNA; shRNA; microRNA; antagomirs; antisense oligonucleotides; DNA; RNA; therapeutics aptamer; cancer; iRNA; siRNA; shRNA; microRNA; antagomirs; antisense oligonucleotides; DNA; RNA; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Soldevilla, M.M.; Meraviglia-Crivelli de Caso, D.; Menon, A.P.; Pastor, F. Aptamer-iRNAs as Therapeutics for Cancer Treatment. Pharmaceuticals 2018, 11, 108. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040108

AMA Style

Soldevilla MM, Meraviglia-Crivelli de Caso D, Menon AP, Pastor F. Aptamer-iRNAs as Therapeutics for Cancer Treatment. Pharmaceuticals. 2018; 11(4):108. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040108

Chicago/Turabian Style

Soldevilla, Mario M., Daniel Meraviglia-Crivelli de Caso, Ashwathi P. Menon, and Fernando Pastor. 2018. "Aptamer-iRNAs as Therapeutics for Cancer Treatment" Pharmaceuticals 11, no. 4: 108. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040108

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop